Charo Jehad, Sundbäck Maria, Wasserman Ken, Ciupitu Anne-Marie T, Mirzai Babak, van der Zee Ruurd, Kiessling Rolf
Cancer Center Karolinska (CCK), Karolinska Hospital, S-17176, Stockholm, Sweden.
Infect Immun. 2002 Dec;70(12):6652-7. doi: 10.1128/IAI.70.12.6652-6657.2002.
Although plasmid DNA (pDNA)-based immunization has proven efficacy, the level of immune responses that is achieved by this route of vaccination is often lower than that induced by traditional vaccines, especially for primates and humans. We report here a simple and potent method to enhance pDNA-based vaccination by using two different plasmids encoding viral or bacterial antigens. This method is based on coadministration of low concentrations of a recently described immunopotentiating, Schiff base-forming drug called tucaresol which has led to significant augmentation of antigen-specific humoral and cellular immune responses. Our data suggest that enhancement of the immune response with tucaresol might provide a powerful tool for the further development of pDNA-based immunization for humans.
尽管基于质粒DNA（pDNA）的免疫接种已证明具有疗效，但通过这种疫苗接种途径所实现的免疫反应水平通常低于传统疫苗所诱导的水平，尤其是在灵长类动物和人类中。我们在此报告一种简单而有效的方法，即通过使用两种编码病毒或细菌抗原的不同质粒来增强基于pDNA的疫苗接种。该方法基于共同施用低浓度的一种最近描述的具有免疫增强作用、能形成席夫碱的药物——图卡雷索尔，这已导致抗原特异性体液免疫和细胞免疫反应显著增强。我们的数据表明，用图卡雷索尔增强免疫反应可能为基于pDNA的人类免疫接种的进一步发展提供一个有力工具。
